Gene Therapy Ophthalmology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2017

  • ID: 4330869
  • Report
  • 188 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
“Gene Therapy Ophthalmology Insight - Pipeline Assessment, Market Trend, Technology and Competitive Landscape, 2017” emphasizes on the currently under development Gene Therapy products in Opthalmology.
  • The report covers 15+ companies, which are active in this field with 42 products and various technologies. This report includes: Gene Therapy products in Ophthalmology by companies and Research Activities by Institutes in this area. The report provides in-depth analysis of the product profiles covering their pre-clinical and clinical studies, collaboration details and deal values, technologies and targeted indications. The report further gives information on market drivers and barriers followed by the SWOT Analysis.
Scope:
  • Overview of the Gene Therapy products in Ophthalmology
  • Pipeline scenario of Gene Therapy products in Ophthalmology under development different companies and research institutes
  • Competitive landscape of products
  • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles including: mechanism of action, route of administration and molecule type along with product development activities
  • Coverage of licensors, collaborators and development partners, deal terms and deal values
  • Highlights of latest developmental technologies for Gene Therapy products in Ophthalmology
  • Market drivers and barriers along with the SWOT analysis
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
  • Secondary sources information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and access to available databases.
Note: Delivery of this report takes up to 24 hours after purchase.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  1. Report Introduction
  2. Executive Summary
  3. Overview
  4. Gene Therapy and Ophthalmology
  5. Gene Transfer Systems
  6. Adenovirus: An Efficient Vector
  7. Competitive Landscape
  8. Collaborations and Deal values
  9. Designation Analysis
  10. Developmental Technologies
  11. Gene Therapy products in Ophthalmology on the basis of Delivery System
  12. Gene Therapy Products in Ophthalmology by Indication
  13. Pipeline Therapeutics (Company Sponsored)
  14. Comparative Analysis
  15. Late Stage Products (Filed and Phase III)
  16. Comparative Analysis
  17. Mid Stage Products (Phase II)
  18. Comparative Analysis
  19. Early Stage Products (Phase I and IND)
  20. Comparative Analysis
  21. Pre-clinical and Discovery Stage Products
  22. Comparative Analysis
  23. Drug Candidate Profiles
  24. SAR 421869: Sanofi
  25. Product Description
  26. Research and Development
  27. Product Development Activities
  28. NSR AAV-RPGR: NightstaRx Limited
  29. Product Description
  30. Research and Development
  31. Product Development Activities
  32. Therapeutic Assessment: Active Products (Company Sponsored)
  33. Assessment by Monotherapy Products
  34. Assessment by Route of Administration
  35. Assessment by Stage and Route of Administration
  36. Assessment by Stage and Molecule Type
  37. Discontinued Products
  38. Comparative Analysis
  39. Drug Name: Company Name
  40. Product Description
  41. Research and Development
  42. Product Development Activities
  43. Dormant Products
  44. Comparative Analysis
  45. Drug Name: Company Name
  46. Product Description
  47. Research and Development
  48. Product Development Activities
  49. Research Activities by Institutions
  50. Drug Name: Institute Name
  51. Product Description
  52. Research and Development
  53. Product Development Activities
  54. Market Barriers and Drivers
  55. Drivers
  56. Barriers
  57. SWOT Analysis
  58. Appendix
  59. Methodology
  60. Consulting Services
  61. Disclaimer
  62. Report Purchase Options
  63. About Us
List of Tables
Table 1: Characteristic features of gene transfer viral vectors
Table 2: Collaboration and Deal Values for Gene Therapies in Ophthalmology
Table 3: Designation Analysis for Gene Therapies in Ophthalmology
Table 4: Companies and their Technologies for Gene Therapies in Ophthalmology
Table 5: Gene Therapy products in Ophthalmology on the basis of Delivery System
Table 6: Gene Therapy Products in Ophthalmology by Indication
Table 7: Total Products for Gene Therapy Ophthalmology
Table 8: Late Stage Products (Filed and Phase III)
Table 9: Mid Stage Products (Phase II)
Table 10: Early Stage Products (Phase I and IND)
Table 11: Pre-clinical and Discovery Stage Products
Table 12: Assessment by Monotherapy Products
Table 13: Assessment by Route of Administration
Table 14: Assessment by Stage and Route of Administration
Table 15: Assessment by Stage and Molecule Type
Table 16: Discontinued Products
Table 17: Dormant Products

List of Figures
Figure 1: Gene Therapy Administration in Ophthalmology
Figure 2: Designation Analysis for Gene Therapies in Ophthalmology
Figure 3: Gene Therapy products in Ophthalmology on the basis of Delivery System
Figure 4: Total Products for Gene Therapy Ophthalmology
Figure 5: Late Stage Products (Filed and Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical and Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Route of Administration
Figure 11: Assessment by Stage and Route of Administration
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Discontinued Products
Figure 14: Dormant Products
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll